Patents for A61P 35 - Antineoplastic agents (221,099)
05/2009
05/28/2009US20090137559 Bazedoxifene ascorbate
05/28/2009US20090137555 activity of CDK1, CDK2, CDK4, CDK5, GSK3 beta , Bcr-ab1, Flt-3, c-Kit, PDGFR beta , Src, Mek1 and CK1; 2-[N'-(2,3-dibromo-8-oxo-5,6,7,8-tetrahydro-1H-pyrrolo[2,3-c]azepin-4-ylidene)-hydrazino]-benzoic acid; antiinflammatory agent; autoimmune, neurological, cardiovasculal, hormone-related diseases
05/28/2009US20090137552 Organic Compound
05/28/2009US20090137532 Aldolase-inhibiting aromatic compounds
05/28/2009US20090137521 Certain Compounds, Compositions and Methods
05/28/2009US20090137513 RNA Interference Mediated Inhibition of Acetyl-CoA-Carboxylase Gene Expression Using Short Interfering Nucleic Acid (siNA)
05/28/2009US20090137512 nucleotide sequence complementary to a target RNA sequence and a second sequence chemically modified so it can no longer act as a guide sequence for mediating RNA interference, having complementarity to said first sequence; cancer, proliferative diseases
05/28/2009US20090137511 RNA INTERFERENCE MEDIATED INHIBITION OF PLACENTAL GROWTH FACTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
05/28/2009US20090137509 RNA INTERFERENCE MEDIATED INHIBITION OF PROLIFERATION CELL NUCLEAR ANTIGEN (PCNA) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
05/28/2009US20090137508 Treatment of any disease that responds to modulation of gene expression, for example cancer, proliferative, inflammatory, metabolic, autoimmune, neurologic, ocular diseases; in vivo stability and bioavailability
05/28/2009US20090137503 Pharmacological modulation of telomere length in cancer cells for prevention and treatment of cancer
05/28/2009US20090137494 Tumor-activated prodrug compounds and treatment
05/28/2009US20090137493 Inhibition of tumor metastases using protein kinase C (PKC) inhibitors
05/28/2009US20090137482 Biologically active peptide and agent containing the same
05/28/2009US20090137476 Apo-2 ligand variants and uses thereof
05/28/2009US20090137473 Inhibition of microtubule protrusion in cancer cells
05/28/2009US20090137470 Methods of treating cancer using notch pathway inhibitors
05/28/2009US20090137468 Cytotoxic factors for modulating cell death
05/28/2009US20090137453 Composition comprising at least one oxazoline to inhibit migration of langerhans cells, and uses thereof
05/28/2009US20090137451 Methods for Assessing Suitability of Cancer Patients for Treatment with Histone Deacetylase Inhibitors
05/28/2009US20090137412 Chromogenic in situ hybridization methods, kits, and compositions
05/28/2009US20090137036 Tweak receptor
05/28/2009US20090137035 Tweak receptor
05/28/2009US20090137002 Anti ephb4 antibodies and antibody fragments
05/28/2009US20090136999 Compositions and methods for immunotherapy of cancer and infectious diseases
05/28/2009US20090136980 screening for a therapeutic oligopeptide for treatment of tumor disorders; contacting the tumor with a therapeutically effective amount of a CD10 cleavable prodrug, wherein tumor is comprised of one or more target cells which express CD10 for at least a portion of the target cell life cycle
05/28/2009US20090136970 Nogo receptor homologues and their use
05/28/2009US20090136939 Methods for diagnosis and therapy for pancreatic cancer and composition useful therein
05/28/2009US20090136928 Compositions and Methods for the Diagnosis and Treatment of Tumor
05/28/2009US20090136566 Therapeutic triterpenoids
05/28/2009US20090136556 System And Method For Coating Implantable Devices
05/28/2009US20090136528 Novel immunogenic epitope for immunotherapy
05/28/2009US20090136527 Synthetic peptide comprising the amino acid sequence GPRLGYSWHX in which each of the amino acids are in the D-amino acid configuration and X is any amino acid; optionally conjugated to the natural gonadotropin-releasing hormone peptide; vaccines for use incontrolling fertility or heat in an animal
05/28/2009US20090136524 Compositions and methods for diagnosis and treatment of tumors
05/28/2009US20090136520 Mitochondrial localization of muc1
05/28/2009US20090136517 Combined treatment with an egfr kinase inhibitor and an inhibitor of c-kit
05/28/2009US20090136513 Bicyclo-pyrazoles active as kinase inhibitors
05/28/2009US20090136508 Method of diagnosing colon and gastric cancers
05/28/2009US20090136502 Preventives/Remedies for Cancer
05/28/2009US20090136499 RAF Inhibitors and Uses Thereof
05/28/2009US20090136496 Chronic lymphocytic leukemia prognosis and treatment
05/28/2009US20090136494 Combination therapies employing GITR binding molecules
05/28/2009US20090136489 Methods for the treatment, diagnosis, and prognosis of cancer
05/28/2009US20090136487 Bmx mediated signal transduction in irradiated vascular endothelium
05/28/2009US20090136486 Biomarkers for human papilloma virus-associated cancer
05/28/2009US20090136485 Methods and compositions for inhibiting CD32B expressing cells
05/28/2009US20090136484 Novel antibody molecules and nucleic acids
05/28/2009US20090136483 Compositions and Methods for Binding Lysophosphatidic Acid
05/28/2009US20090136478 Methods for using enzymes to disintegrate cancerous tumors in vivo
05/28/2009US20090136475 Immunokinases
05/28/2009US20090136473 Biaryl pde4 inhibitors for treating pulmonary and cardiovascular disorders
05/28/2009US20090136458 Renal Carcinoma Cell Line and Uses thereof
05/28/2009US20090136451 Humanised Baculovirus
05/28/2009US20090136431 Stilbene Like Compounds as Novel HDAC Inhibitors
05/28/2009US20090136421 PAI-2 conjugates for the treatment and imaging of cancer
05/28/2009US20090136420 Neoplasm-specific polypeptides and their uses
05/28/2009US20090136419 parenterally administering a dose of samarium ethylenediaminetetramethylenephosphonic acid (EDTMP); and carboplatin or taxoids; anticarcinogenic, antitumor, and antantiproliferative agents; autoimmune, infectious , metabolic or genetic disorders
05/28/2009DE102007056424A1 Pharmazeutische Zusammensetzung, enthaltend eine Öl/Wasser-Emulsion A pharmaceutical composition containing an oil / water emulsion
05/28/2009CA2706536A1 Amorphous body composed of heterocyclic compound, solid dispersion and pharmaceutical preparation each comprising the same, and process for production of the same
05/28/2009CA2706201A1 Peptides with capacity to bind to scurfin and applications
05/28/2009CA2706102A1 Small-molecule modulators of trp-p8 activity
05/28/2009CA2706075A1 Cancer diagnostic and therapeutic methods that target plk4/sak
05/28/2009CA2705944A1 Methods and compositions for inhibiting integrins using tellurium-containing compounds
05/28/2009CA2705588A1 System for delivery into a xcr1 positive cell and uses thereof
05/28/2009CA2704214A1 Pyrimidine derivatives for the treatment of asthma, copd, allergic rhinitis, allergic conjunctivitis, atopic dermatitis, cancer, hepatitis b, hepatitis c, hiv, hpv, bacterial infections and dermatosis
05/28/2009CA2703893A1 Compound
05/28/2009CA2703283A1 Method for treating hematopoietic neoplasms
05/28/2009CA2699306A1 Sunitinib hemi-l-malate, polymorphs and preparation thereof, polymorphs of racemic sunitinib malate, compositins containing sunitinib base and malic acid and preparation thereof
05/28/2009CA2699305A1 Polymorphs of sunitinib base and processes for preparation thereof
05/28/2009CA2695605A1 Pyrazolone derivative emulsion formulations
05/27/2009EP2062971A1 Chimeric adenovirus, method for producing the same and pharmaceutical using the same
05/27/2009EP2062919A2 Pharmaceutical compositions and methods useful for modulating angiogenesis, inhibiting metastasis and tumor fibrosis, and assessing the malignancy of colon cancer tumors
05/27/2009EP2062918A2 Pharmaceutical compositions and methods useful for modulating angiogenesis, inhibiting metastasis and tumor fibrosis, and assessing the malignancy of colon cancer tumors
05/27/2009EP2062914A2 Somatostatin-dopamine chimeric analogs
05/27/2009EP2062893A1 Fused imidazoles for cancer treatment
05/27/2009EP2062890A1 Tricyclic thrombin receptor antagonist
05/27/2009EP2062887A1 Novel aminopyridine derivative having aurora a-selective inhibitory activity
05/27/2009EP2062886A1 Salt of phenoxypyridine derivative or crystal thereof and process for producing the same
05/27/2009EP2062885A1 Acid addition salts of imatinib and formulations comprising the same
05/27/2009EP2062884A1 Novel phenylacetic acid derivative
05/27/2009EP2062879A1 Heterocyclic inhibitors of p38
05/27/2009EP2062597A1 Preventive or remedy for er-negative and her2-negative breast cancer and method of screening the same
05/27/2009EP2062596A1 Anti-tumor agent
05/27/2009EP2062592A1 System for delivery into a XCR1 positive cell and uses thereof
05/27/2009EP2062584A1 Adhesive preparation
05/27/2009EP2062583A2 Therapeutic applications of pro-apoptotic benzodiazepines
05/27/2009EP2062577A1 Oleanolic acid derivatives as NO production inhibitors
05/27/2009EP2061814A2 Antibodies and immunoconjugates and uses therefor
05/27/2009EP2061795A2 Pyrrolo[2,1-c][1,4]benzodiazepine hybrids and a process for the preparation thereof
05/27/2009EP2061794A2 2-phenoxy pyrimidinone analogues
05/27/2009EP2061790A1 Substituted aminopyrazolopyridines and salts thereof, their preparations and pharmaceutical compositions comprising them
05/27/2009EP2061786A2 Indazole derivatives as modulators of interleukin-1 receptor-associated kinase
05/27/2009EP2061782A1 Novel aminopyridine derivatives having aurora a selective inhibitory action
05/27/2009EP2061772A2 Multi-functional small molecules as anti-proliferative agents
05/27/2009EP2061768A2 Imidazole-4,5-dicarboxamide derivatives as jak-2 modulators
05/27/2009EP2061761A1 Phenethylamide derivatives with kinase inhibitory activity
05/27/2009EP2061749A1 Positively charged water-soluble prodrugs of acetaminophen and related compounds with very fast skin penetration rate
05/27/2009EP2061561A1 Methods and compositions for treating cancer
05/27/2009EP2061514A2 An aqueous formulation for selective targeting and delivering gene to cancer cells
05/27/2009EP2061510A1 Treatment and/or prevention of non-infectious medical conditions using antibody-containing compositions